2021
DOI: 10.1530/ec-21-0258
|View full text |Cite
|
Sign up to set email alerts
|

A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism

Abstract: Primary hyperparathyroidism (pHPT) is a common endocrine disorder that can be cured by parathyroidectomy, and patients unsuitable for surgery can be treated with cinacalcet. Availability of surgery may be reduced during COVID-19 and cinacalcet can be used as bridging therapy. In this single centre retrospective analysis, we investigated the efficacy and safety of cinacalcet in patients with pHPT receiving cinacalcet between March 2019 and July 2020, including pre-parathyroidectomy bridging. We reviewed and su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 17 publications
1
3
0
Order By: Relevance
“…Since PTH values are reduced under therapy with cinacalcet, the question arises as to whether PTH dynamics during the intraoperative monitoring are influenced as a result. Calcimimetic therapy was applied more commonly in our patient collective with the beginning of the COVID-19 pandemic, in 64% of the patients, which is in accordance with published evidence and the recommendation of the European Society for Endocrinology [ 12 , 14 ].…”
Section: Discussionsupporting
confidence: 84%
See 3 more Smart Citations
“…Since PTH values are reduced under therapy with cinacalcet, the question arises as to whether PTH dynamics during the intraoperative monitoring are influenced as a result. Calcimimetic therapy was applied more commonly in our patient collective with the beginning of the COVID-19 pandemic, in 64% of the patients, which is in accordance with published evidence and the recommendation of the European Society for Endocrinology [ 12 , 14 ].…”
Section: Discussionsupporting
confidence: 84%
“…Elective parathyroidectomy for pHPT has been frequently postponed in the era of the COVID-19 pandemic, and the European endocrinology guidelines proposed that cinacalcet should be considered as a bridging therapy while operation capacity is reduced [ 14 ]. However, calcimimetic therapy has increasingly been reported to be useful in improving preoperative biochemical parameters in pHPT even before the COVID-19 pandemic [ 12 , 15 ]. The drop in efficacy of this therapy, and sometimes its biochemical normalization, was reported in the results of a randomized controlled study and a systemic review [ 16 , 17 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations